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Abstract
Background: Activated platelets release serotonin that binds 5-HT2B receptor on fibroblasts leading to fibroblast
activation. Clopidogrel, an inhibitor of ADP-dependent platelet activation prevents fibrosis in animal models of
systemic sclerosis (SSc). We aimed at assessing whether i) ADP-dependent platelet activation is increased in patients
with SSc compared to healthy subjects and patients with rheumatoid arthritis (RA) and ii) whether clopidogrel can
effectively suppress ADP-dependent activation, reduce circulating serotonin levels and hence, favorably affect
fibrosis or vasculopathy in patients with systemic sclerosis.
Methods: Thirteen patients with SSc were recruited. Platelet activation was assessed by aggregometry prior to and
following 14 days of clopidogrel treatment. At the same time points serotonin and soluble vascular cell adhesion
molecule 1 (s-VCAM1), a marker of endothelial dysfunction, were measured.
Results: ADP-dependent platelet activation was similar between patients with SSc (n = 13), patients with RA (n = 28)
and healthy subjects (n = 22) (mean ± SEM AU*min: 392.1 ± 58.4, 535.5 ± 61.33 and 570.9 ± 42.9 in patients with SSc,
patients with RA and healthy subjects respectively, p = 0.14). Clopidogrel treatment significantly reduced platelet
activation in patients with SSc (mean ± SEM AU*min: 392.1 ± 58.4 vs 163.8 ± 51.7, p = 0.014). Clopidogrel treatment
did not affect serotonin levels but led to a significant increase in s-VCAM1 (p = 0.03). Three patients developed new
digital ulcers during the study. The potential association of the study drug with the development of new digital
ulcers led to early termination of the study.
Conclusion: Clopidogrel may worsen markers of endothelial function and associate with development of new
digital ulcers in patients with SSc.
Clinical trial registration: ISRCTN63206606. Registered 02/Dec/2014.
Keywords: Systemic sclerosis, Scleroderma, Clopidogrel, Digital ulcers, Platelets
* Correspondence: kosdelis@gmail.com
1Division of Rheumatology, Department of Internal Medicine, Patras
University Hospital, University of Patras Medical School, 26504Rion, Patras,
Greece
Full list of author information is available at the end of the article
© 2016 Ntelis et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ntelis et al. BMC Musculoskeletal Disorders  (2016) 17:213 
DOI 10.1186/s12891-016-1072-1
Background
Systemic Sclerosis (SSc) is a systemic rheumatic disease
characterized by obliterative vasculopathy, autoimmunity
and progressive fibrosis leading to tissue injury. The skin
and several internal organs are involved during the disease
course; involvement of vital organs leads to increased
mortality and morbidity. To date, no approved disease-
modifying therapies exist for the treatment of patients
with SSc. Numerous experimental drugs or interventions
have been investigated for the treatment of visceral fibro-
sis in systemic sclerosis, some of them demonstrating
promising results [1–4]. However, the need for new thera-
peutic targets in SSc remains crucial.
The main pathogenetic model of SSc recognizes endo-
thelial cell injury, immune activation and fibrosis as the
key points in the disease process [5, 6]. Lately, accumulat-
ing evidence suggests that platelets are not just cell frag-
ments regulating hemostasis, but may be active players in
the pathogenesis of several inflammatory or autoimmune
diseases, including SSc [7–9]. Evidence suggests that there
may be increased platelet activity in patients with SSc, due
to the underlying vascular damage [10, 11] and many
platelet-derived molecules, such as beta-thromboglobulin,
thromboxane B2 and platelet factor 4, have been reported
to be elevated in patients with SSc [12, 13]. A recent study
has provided evidence that serotonin (5-hydroxytrypta-
mine [5-HT]) released in peripheral tissues upon activa-
tion of platelets may induce skin fibrosis through
activation of fibroblasts via 5-HT2B receptors [14]. These
data point to the direction of a novel pathogenetic model
of SSc where platelets and serotonin act as the link be-
tween endothelial dysfunction and fibrosis (endothelial
dysfunction→ platelet activation→ serotonin release→
fibroblast activation→ fibrosis). Moreover, inhibition of
platelet activity by clopidogrel treatment leads to a reduc-
tion of fibrosis in bleomycin-induced and tight skin mur-
ine models of scleroderma [14]. It is not known whether
serotonin levels are increased in patients with SSc, but it
has been found to be elevated in closely related condi-
tions, such as Raynaud’s phenomenon and pulmonary
hypertension [15, 16]. Antiplatelet agents, such as aspirin,
which have been used previously in patients with SSc in
order to improve vasculopathy have failed to show any
efficacy [17]. So far, the effect of platelets inhibition by
clopidogrel, a P2Y12 receptor antagonist, has not been
investigated in vivo in patients with SSc. Clopidogrel is
indicated for adult patients suffering from myocardial
infarction or acute coronary syndrome, ischemic stroke or
established peripheral arterial disease. Clopidogrel inhibits
adenosine diphosphate (ADP) binding to its platelet P2Y12
receptor and subsequently the ADP-mediated activation
of the glycoprotein GPIIb/IIIa complex, thereby inhibiting
platelet aggregation. ADP-dependent platelet activation is
one of the pathways which lead to platelet activation.
In this study we aimed to assess whether i) ADP-
dependent platelet activation is increased in patients
with SSc compared to healthy subjects and patients
with rheumatoid arthritis (RA) and ii) whether clopidogrel
can a) effectively suppress ADP-dependent activation of
platelets, b) reduce circulating levels of serotonin, a sig-
nificant profibrotic mediator and finally c) favorably affect
fibrosis or vasculopathy in patients with systemic sclerosis.
We report herein that clopidogrel effectively inhibits ADP-
dependent activation of platelets but does not improve
either fibrosis or endothelial function in patients with SSc.
To the contrary, it may associate with a deterioration of




We enrolled 14 patients with a diagnosis of SSc, fulfilling
the 2013 ACR/EULAR criteria for the classification of
the disease [18]. One patient did not comply with treat-
ment and was withdrawn from the study. Baseline demo-
graphic and clinical characteristics of the remaining 13
patients are presented in Table 1. Most patients were
female (n = 12) with a mean age of 59.5 years and had
limited disease (n = 8) with a mean disease duration of
10.9 years. All patients underwent a complete physical
examination and a detailed review of their medical files
prior to study enrolment. Other variables were also evalu-
ated (full blood count, biochemistry profile, autoantibody
profiles, electrocardiogram and cardiac ultrasound). All
patients were Anti-Scl-70 (anti-topoisomerase I antibodies)
or anti-ACA (anti-centromere antibodies) positive (n = 5
and n = 8 respectively) and had no change in medications
administered during the last 6 months before enrollment.
None of the study subjects was under any kind of antiplate-
let treatment. No change in immunosuppressive treatment
was allowed during the study. Exclusion criteria included
a history of gastrointestinal or cerebral bleeding. ADP-
dependent platelet activation was also measured in 28
patients with RA and 22 healthy subjects for control
purposes. Most patients with RA were female (75 %) with
a mean age of 59 years and a mean DAS28 of 2.9; no
patient was receiving any antiplatelet agent. The majority
of the patients with RA were on treatment only with
synthetic DMARDs (71.4 %), mainly methotrexate, while
the rest of them were receiving also a biologic DMARD
(28.6 %). No patient was receiving drugs, such as antide-
pressants (including selective serotonin reuptake inhibi-
tors, serotonin and noradrenaline reuptake inhibitors and
tricyclic anti-depressants), any kind of anti-psycotic agent,
anti-migraine agents (triptans), anti-convulsants, anti-
parkinsonian agents, opioids and tramadol, that interfere
with levels of serotonin. Healthy subjects were mostly
female (90.9 %) with a mean age of 55 years and were not
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on any kind of antiplatelet or other treatment. APA and
DD formed the Safety Board of the study and were respon-
sible for evaluating all adverse events.
Treatment
Patients with SSc were treated with the recommended
dose of clopidogrel in everyday clinical practice (75 mg).
Duration of the study had been planned to be 2 years.
Finally, due to early discontinuation of the study, 12
patients completed 1 year of treatment, while one patient
(#13) was treated with the study drug for 10 months.
Indices of internal organ function
Standard PFTs (pulmonary function tests) were performed
every 6 months during the study, including assessment of
forced vital capacity (FVC) and diffusing capacity of carbon
monoxide (DLco) corrected for hemoglobin concentration.
PFT parameters are expressed as a percentage of nor-
mal predicted values. Estimated glomerular filtration rate
(eGFR) was calculated at baseline and at 1 year with the 4
variables MDRD (Modification of Diet in Renal Disease
Study Group) formula [19]. Complete cardiac ultrasound
study was performed at baseline and at 12 months and
right ventricular systolic pressure (RVSP) was determined.
Overall functional impairment
Assessment of functional status was performed at base-
line, 6 and 12 months using the modified for Scleroderma
Health Assessment Questionnaire (SHAQ) [20].
Clinical assessment of skin thickening
The modified Rodnan skin score (MRSS) [21, 22] was
used for clinical assessment of skin thickening at baseline
and at 1 year, by two experienced assessors (DD and KN).
Levels of circulating serotonin and s-VCAM1
Whole blood was obtained from all participants at base-
line and following 14 days of treatment. Platelet poor
plasma was isolated from citrate tubes following a
double centrifugation at 2000 g. Following the first cen-
trifugation the top 75 % of plasma was removed with a
plastic pipette, avoiding contamination, and underwent a
second centrifugation at 2000 g. After the second centri-
fugation, the upper 75 % purified from the sedimented
platelets, formed the platelet poor plasma. Samples from
strenuous punctures were excluded. Serotonin was mea-
sured in these specimens with Radioimmunoassay (RIA)
technique (DIAsource ImmunoAssays). Serum was also
isolated at the same time points in order to evaluate the
effect of treatment on the circulating levels of soluble
vascular cell adhesion protein 1 (s-VCAM1), a marker of
endothelial dysfunction [23]. Enzyme-linked immuno-
sorbent assay (ELISA) technique was employed, using
commercially available kit, according to the manufac-
turer’s instructions (R&D Systems, Minneapolis MN,
USA). All samples were stored at -70 ° C.
Assessment of ADP-dependent activation of platelets
The effect of treatment upon platelet activity was assessed
through ADP-induced aggregation of platelets, measured
by Multiplate Analyser (Roche), an instrument with five
channels for parallel aggregometry measurements. Platelet
activation was measured at baseline, following 14 days and
1 year of treatment. After 1:2 dilution of whole blood with
0.9 % NaCl solution and incubating for 3 min in the test
cuvettes at 37 °C, the agonist (ADP) was added. Platelet
aggregation was continuously recorded for 6 min. The
adhesion and aggregation of platelets was measured by
the change of electrical resistance between two sensor
wires. Impedance is transformed to arbitrary aggregation
units (AU) that are plotted against time (AU*min) [24].
Resistance to clopidogrel inhibition was defined as a
AU*min value ≥468 on treatment [25].
Statistical analysis
Statistical analysis was performed using the GraphPad
Prism software version 5. All variables were tested for
normality using D'Agostino's test. Data are presented as
mean ± SEM, median or percentages, as appropriate. The
paired Student’s t-test and Wilcoxon matched pairs test,
were used as indicated, for normal and non-normal distri-
butions respectively. One-way ANOVA was used for group
comparisons. Unpaired t-test was used to compare un-
paired values. Correlations between ADP-dependent













1/F/47 5 limited GI -
2/F/62 12 diffuse Lung,PAH,GI CYC
3/M/55 2 limited Lung,GI -
4/F/53 12 diffuse Lung,DU,GI MMF, Bos
5/F/53 12 limited Lung,DU,GI Pred, RTX, Bos
6/F/78 4 diffuse Lung,DU,PAH,Musc Pred, Bos, RTX
7/F/57 21 limited Lung,DU,GI Pred, Bos
8/F/58 3 diffuse Lung,GI RTX
9/F/66 9 limited Lung,GI MMF
10/F/59 17 limited Musc –
11/F/65 8 limited Lung,GI RTX
12/F/40 22 diffuse Lung,GI,Musc RTX
13/F/81 15 limited GI –
Pred: low dose prednisone; Bos: bosentan; MMF: mycophenolate mofetil; CYC:
cyclophosphamide; RTX: rituximab
DU: digital ulcers; Musc: musculoskeletal involvement; GI: gastrointestinal
involvement; PAH: pulmonary arterial hypertension
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platelet activation and other variables were analyzed
by Pearson or Spearman test, as appropriate. Values
of p < 0.05 were considered as statistically significant.
Results
No evidence of increased ADP-dependent platelet
activation in patients with SSc
We first evaluated the ADP-dependent activation of
platelets in patients with SSc compared to patients with
RA and healthy subjects. No statistically significant dif-
ferences were found between patients with SSc (n = 13),
patients with RA (n = 28) and healthy subjects (n = 22)
(mean ± SEM AU*min: 392.1 ± 58.4, 535.5 ± 61.33 and
570.9 ± 42.9 in patients with SSc, patients with RA and
healthy subjects respectively, p = 0.14). These data are
diagrammatically depicted in Fig. 1a.
Since many patients in our cohort had long standing
disease we next sought to explore whether ADP-dependent
platelet activation in patients with SSc correlates with
disease duration. We found that ADP-dependent platelet
activation in patients with early disease (as defined by
disease duration ≤ 4 years, n = 3) was similar to that of
patients with long standing disease (mean ± SEM AU*min:
315.7 ± 105.4 vs 415.0 ± 70.1 in patients with early vs late
disease, respectively, p = 0.49). Moreover, no significant
association of ADP-dependent platelet activation with age,
gender, PFTs or MRSS in patients with SSc was found.
These data indicate that ADP-dependent platelet activa-
tion is not increased in patients with SSc, even in those
with early disease despite the underlying vasculopathy;
therefore, this particular pathway of platelet activation does
not seem to be crucially involved in SSc pathogenesis.
Clopidogrel treatment effectively inhibits ADP-dependent
activation of platelets in patients with SSc
We next assessed the effect of clopidogrel on ADP-
dependent activation of platelets in patients with SSc.
Following 14 days of clopidogrel treatment a significant
reduction of ADP-depended activation of platelets was
found in patients with SSc (mean ± SEM AU*min: 392.1
± 58.4 vs 163.8 ± 51.7, prior to and following treatment
respectively, p = 0.014). These data are shown in Fig. 1b.
This effect was sustained following one year of treatment
(mean ± SEM AU*min: 157.2 ± 39, p = 0.005 compared
to baseline). Two patients (15.4 %) showed resistance to
clopidogrel inhibition and displayed high platelet reactiv-
ity (497 and 594 AU*min) despite treatment. These data
show that clopidogrel is an effective inhibitor o ADP-
dependent platelet activation in patients with SSc since
the percentage of patients displaying resistance to clopi-
dogrel inhibition (15.4 %) is even lower than that re-
ported for the general population which is estimated to
be up to 30 % [26, 27].
Clopidogrel treatment does not affect serotonin levels
We next assessed whether effective suppression of ADP-
dependent platelet activation by clopidogrel can decrease
circulating serotonin levels, a significant profibrotic
mediator. Serotonin levels in platelet poor plasma did not
change following 14 days of treatment with clopidogrel
(mean ± SEM ng/dl: 178.3 ± 17.4 vs 210.6 ± 28.6, prior to
and following treatment respectively, p = 0.17), despite the
effective suppression of ADP-dependent activation of
platelets at the same time point. Data are shown in Fig. 2a.
Clopidogrel treatment associates with worsening of
endothelial function
We further evaluated the results of clopidogrel treatment
on soluble VCAM1 levels as a marker of endothelial
dysfunction/injury. There was a statistically significant
increase of s-VCAM1 levels following 14 days of clopido-
grel treatment (optical density mean ± SEM: 2.339 ± 0.211
vs 2.651 ± 0.139 before and following treatment respect-
ively, p = 0.03) as shown in Fig. 2b. These data indicate
Fig. 1 ADP-dependent platelet activation in patients with SSc is not increased compared to patients with RA and healthy subjects
(a). Clopidogrel effectively inhibits ADP-dependent platelet activation in patients with SSc (b)
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that clopidogrel treatment does not improve but may ac-
tually worsen endothelial function in patients with SSc.
Clopidogrel treatment may associate with the
development of new digital ulcers in patients with SSc
Three patients, all with limited disease, developed new
digital ulcers during the study; 2 of them did not have a
history of digital ulcers. Patient #3 had early disease with a
3 year history of Raynaud’s phenomenon before the diagno-
sis, but no history of ulcers. Most striking, patient #13 had
a longstanding disease of 15 years; she never had digital ul-
cers. Patient #4 had a 12 year history of disease but she has
not developed any ulcers for the last 8 years, while on
bosentan treatment. Patients #3, #4 and #13 developed the
ulcers following 10, 9 and 10 months of treatment, respect-
ively. In patients #13 and #3 we initiated treatment with
bosentan with a good response after a short period, while
patient #4 was treated with iloprost and antibiotics showing
also a rapid improvement. None of the patients had any
changes in everyday lifestyle during the study including
exposure to cold. Following the development of digital ul-
cers in patient #13 the Safety Board of the study decided to
withdraw all patients from the study medication, conclud-
ing that there may be an association between treatment
and development of new ulcers. At that time point all
patients, apart from patient #13, had completed 1 year on
treatment. No other serious adverse events were recorded
during the study. The main side effects included a transient
rash after treatment initiation in patient #7 and minor
bruising episodes in patients #5 and #9.
Effect of Clopidogrel treatment on clinical outcomes
To evaluate any potential clinical effect of clopidogrel treat-
ment we performed a complete physical exam, evaluation
of skin thickening, evaluation of pulmonary function, basic
laboratory work up and finally evaluation of general func-
tional status. Clopidogrel treatment had no significant effect
on skin thickening (mean ± SEM 10.69 ± 0.62 vs 9.85 ± 0.84
at baseline vs 1 year, respectively, p = 0.12). We did not de-
tect any statistically significant differences in all indices of
internal organ function we examined. FVC remained stable
following 1 year of treatment (mean ± SEM 93.75 ± 5.58 vs
92.67 ± 5.04 at baseline vs 1 year, respectively, p = 0.69), the
same was found for DLco (mean ± SEM 65.08 ± 4.31 vs
62.67 ± 4.85 at baseline vs 1 year respectively, p = 0.39).
SHAQ also showed no significant change following one
year of treatment with clopidogrel (mean ± SEM: 0.80 ±
0.11 vs 0.98 ± 0.14, p = 0.16). RVSP and EGFR also
remained stable following 1 year of treatment. Data are
diagrammatically shown in Fig. 3.
Discussion
We report herein the results of an open label, proof of
principle study evaluating the efficacy of clopidogrel in
patients with SSc. So far, ADP-dependent platelet activa-
tion has not been investigated in SSc with newer tech-
niques. The potential role of platelets in the pathogenesis
of SSc has been explored in SSc but data are still contro-
versial. Several studies demonstrate increased platelet
activation using different agents as agonists [28, 29], but
this was not a consisted finding [30].
In our study we found no evidence of increased ADP-
dependent platelet activation in patients with SSc, even
in those with early disease, compared to patients with
RA and healthy subjects, indicating that this particular
pathway of platelet activation may not be crucially in-
volved in SSc pathogenesis. However, one should take
into account that SSc is an extremely heterogeneous
disease and therefore, definite conclusions cannot be
drawn based on data derived from a small number of
patients. One cannot exclude the possibility that there
Fig. 2 Effect of clopidogrel on serotonin and sVCAM1 levels. No change in serotonin levels in platelets poor plasma was found in patients with
SSc following 14 days of treatment with clopidogrel (a). sVCAM1 levels are significantly increased following clopidogrel treatment in patients with
SSc (b)
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may be a subset of patients with SSc displaying in-
creased ADP dependent platelet activation; we cannot
rule out that in these particular patients clopidogrel
might have some efficacy.
Moreover, we demonstrated that clopidogrel can effect-
ively inhibit the ADP-dependent activation of platelets in
the majority of SSc patients. Previous studies have re-
ported that resistance to clopidogrel inhibition in particu-
lar populations, such as patients with chronic kidney
failure under hemodialysis, can reach up to 84 % [31]. In
our study only two of 13 SSc patients showed resistance
to clopidogrel; this percentage (15.4 %) is even lower than
that reported for the general population, which is esti-
mated to be up to 30 % [26, 27].
Based on experimental data which indicate that platelets
may be involved in the fibrotic process, we aimed at
exploring whether platelet inhibition by clopidogrel could
favorably affect fibrosis in patients with SSc, offering thus
an adjunct therapeutic approach for the disease. There is
evidence that serotonin is an important mediator in SSc
which links vascular damage, platelets and fibrosis. Sero-
tonin, a molecule stored in platelets, has been shown to
possess profibrotic properties [32, 33]. However, there is
no robust evidence that plasma free serotonin is increased
in SSc. Biondi et al reported such a finding in patients with
secondary Raynaud’s phenomenon [15], but Klimiuk et al
found no evidence of this increase in patients with SSc [34].
In our study, effective inhibition of ADP dependent platelet
activation with clopidogrel did not affect serotonin levels.
Finally, our data suggest that clopidogrel may associate
with worsening of endothelial function and development
of new digital ulcers in patients with SSc. Although plate-
lets are considered to promote vasoconstriction, it is also
known that they produce nitric oxide (NO) as well [35].
NO is a vasodilator which mainly derives from endothelial
cells and consists an important modulator of vascular
tone. It has been found that NO production from platelets
is increased in chronic kidney failure [36], another condi-
tion characterized by generalized vasculopathy, and may
have a protective role against cardiovascular risk. In
addition, there are also studies demonstrating some pro-
tective features of platelets regarding fibrosis and vascular
function. In two murine models of liver damage platelets
seem to prevent fibrosis [37] and promote liver tissue
repair [38]. Joshi et al showed that platelet depletion
delays resolution of necrosis in the postischemic liver,
suggesting that the presence of platelet-derived factors is
necessary for tissue remodeling [37].
Moreover, Holowatz et al reported that platelet inhib-
ition with clopidogrel attenuated reflex vasodilation, in
middle aged women, suggesting platelet involvement in
reflex vasodilation through the release of vasodilating
Fig. 3 Effects of clopidogrel on clinical outcomes. Clopidogrel treatment does not have any significant impact on clinical outcomes
(MRSS (a), FVC (b), DLco (c) and EGFR (d)) in patients with SSc
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factors. Investigators found that clopidogrel decreased
skin blood flow responses during hyperthermia [39]. This
effect may be of importance in SSc patients and may
explain the development of new digital ulcers in our study.
All the above data suggest that platelets under certain
conditions may have properties which improve endothelial
function and enhance vasodilation and tissue repair, rather
than provoke tissue injury.
Conclusions
Overall, our data indicate that clopidogrel may associate
with worsening of endothelial function and development
of new digital ulcers in patients with systemic sclerosis.
This study in combination with previous reports of failure
of antiplatelet agents in SSc, indicates that platelets may
not play a crucial role in SSc pathophysiology, at least in
late stages. Moreover, our data indicate that clopidogrel
should be used cautiously in patients with SSc. This be-
comes even more important nowadays, as it is becoming
clear that patients with SSc have increased cardiovascular
morbidity and frequently need antiplatelet treatment [40].
Aspirin may be a more suitable therapeutic option for
these patients. Our findings originate from a small uncon-
trolled trial and further investigation with larger cohorts is
warranted.
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